期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Aerobic vs anaerobic exercise training effects on the cardiovascular system 被引量:3
1
作者 Harsh Patel Hassan Alkhawam +3 位作者 Raef Madanieh Niel Shah constantine e kosmas Timothy J Vittorio 《World Journal of Cardiology》 CAS 2017年第2期134-138,共5页
Physical exercise is one of the most effective methods to help prevent cardiovascular(CV) disease and to promote CV health. Aerobic and anaerobic exercises are two types of exercise that differ based on the intensity,... Physical exercise is one of the most effective methods to help prevent cardiovascular(CV) disease and to promote CV health. Aerobic and anaerobic exercises are two types of exercise that differ based on the intensity, interval and types of muscle fibers incorporated. In this article, we aim to further elaborate on these two categories of physical exercise and to help decipher which provides the most effective means of promoting CV health. 展开更多
关键词 CARDIOVASCULAR EXERCISE TRAINING AEROBIC ANAEROBIC
下载PDF
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
2
作者 constantine e kosmas Andreas Sourlas +2 位作者 Delia Silverio Peter D Montan eliscer Guzman 《World Journal of Cardiology》 CAS 2019年第11期256-265,共10页
Cardiovascular disease(CVD)remains a major cause of morbidity and mortality worldwide.Currently,it is well established that dyslipidemia is one of the major risk factors leading to the development of atherosclerosis a... Cardiovascular disease(CVD)remains a major cause of morbidity and mortality worldwide.Currently,it is well established that dyslipidemia is one of the major risk factors leading to the development of atherosclerosis and CVD.Statins remain the standard-of-care in the treatment of hypercholesterolemia and their use has significantly reduced cardiovascular morbidity and mortality.In addition,recent advances in lipid-modifying therapies,such as the development of proprotein convertase subtilisin/kexin type 9 inhibitors,have further improved cardiovascular outcomes in patients with hypercholesterolemia.However,despite significant progress in the treatment of dyslipidemia,there is still considerable residual risk of recurring cardiovascular events.Furthermore,in some cases,an effective therapy for the identified primary cause of a specific dyslipidemia has not been found up to date.Thus,a number of novel pharmacological interventions are under early human trials,targeting different molecular pathways of lipid formation,regulation and metabolism.This editorial aims to discuss the current clinical and scientific data on new promising lipidmodifying therapies addressing unmet needs in CVD,which may prove beneficial in the near future. 展开更多
关键词 Lipid-modifying THERAPIES CARDIOVASCULAR disease DYSLIPIDEMIA
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部